Form 4: Voyager Therapeutics CEO Alfred Sandrock Sells Shares to Cover Tax Obligations

Voyager Therapeutics CEO Alfred Sandrock sold 10,885 shares of common stock on April 2, 2025, to cover tax obligations related to vesting restricted stock units.

Summary

• On April 2, 2025, Alfred Sandrock, the President and CEO of Voyager Therapeutics, sold 10,885 shares of common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units on April 1, 2025.
• The shares were sold at a weighted average price of $3.43, with individual transactions ranging from $3.34 to $3.52.
• Following the transaction, Sandrock directly owns 430,931 shares of Voyager Therapeutics common stock.
• The sale was not a discretionary trade but rather an automatic sell-to-cover election.

Sentiment

Score: 6

Explanation: The document reports a routine stock sale to cover tax obligations, which is neither particularly positive nor negative. The sentiment is neutral.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and do not necessarily indicate a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares could have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely to be minimal given the relatively small number of shares sold.

Key Dates

Keywords

Voyager Therapeutics, Alfred Sandrock, stock sale, Form 4, tax obligations, restricted stock units, VYGR, CEO